Your browser doesn't support javascript.
loading
Modification in body weight associated with antiepileptic drugs / Alteração de peso corpóreo associado às drogas antiepilépticas
Gaspari, Camilla N. De; Guerreiro, Carlos A. M.
  • Gaspari, Camilla N. De; University of Campinas. Department of Neurology. BR
  • Guerreiro, Carlos A. M; University of Campinas. Department of Neurology. BR
Arq. neuropsiquiatr ; 68(2): 277-281, Apr. 2010. tab, ilus
Article in English | LILACS | ID: lil-545928
ABSTRACT
Antiepileptic drugs (AED) may cause body weight changes.

OBJECTIVE:

To evaluate the dietary habits and body weight associated with AED in epileptic patients.

METHOD:

Sixty-six patients were subjected to two interviews, and had their weight and body mass index calculated and compared at both times, interval between six to eight months.

RESULTS:

It was observed that 59.1 percent showed weight gain. The patients who had no weight gain had a greater proportion of individuals who engaged in some form of physical activity. However, of the 45 patients who maintained their initial dietary and medication pattern, 75.6 percent recorded a weight gain. Weight gain was seen in 66.7 percent of patients on carbamazepine (n=18), 60 percent on valproate (n=5), 50 percent on carbamazepine+clobazam treatment (n=14), and 58.3 percent of patients on other(s) polytherapy (n=12).

CONCLUSION:

The patient should be alerted to possible weight gain, and should be advised about dieting and participating in regular physical activity.
RESUMO
Drogas antiepilépticas (DAE) podem causar alteração do peso corpóreo.

OBJETIVO:

Avaliar o hábito alimentar e do peso corpóreo associado às DAE em pacientes epilépticos.

MÉTODO:

Sessenta e seis pacientes foram submetidos a duas entrevistas, e tiveram peso e índice de massa corpórea (IMC) calculados e comparados nos dois momentos, com intervalo de 6 a 8 meses.

RESULTADOS:

Apresentaram aumento de peso 59,1 por cento dos pacientes. Porém, os pacientes que não tiveram ganho de peso apresentaram maior proporção de indivíduos desenvolvendo alguma atividade física. Enquanto que dentre os 45 que mantiveram o padrão alimentar e medicação inicial 75,6 por cento registraram ganho de peso. Observou-se ganho de peso em 66,7 por cento dos pacientes com carbamazepina (n=18); 60 por cento com valproato (n=5); 50 por cento com carbamazepina e clobazam (n=14); 58,3 por cento dos pacientes com politerapia (n=12).

CONCLUSÃO:

Deve-se alertar o paciente sobre o ganho de peso, orientar quanto à dieta alimentar e, principalmente, incentivar atividade física regular.
Subject(s)

Full text: Available Index: LILACS (Americas) Main subject: Carbamazepine / Weight Gain / Valproic Acid / Anticonvulsants Type of study: Risk factors Limits: Adult / Female / Humans / Male Language: English Journal: Arq. neuropsiquiatr Journal subject: Neurology / Psychiatry Year: 2010 Type: Article Affiliation country: Brazil Institution/Affiliation country: University of Campinas/BR

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: LILACS (Americas) Main subject: Carbamazepine / Weight Gain / Valproic Acid / Anticonvulsants Type of study: Risk factors Limits: Adult / Female / Humans / Male Language: English Journal: Arq. neuropsiquiatr Journal subject: Neurology / Psychiatry Year: 2010 Type: Article Affiliation country: Brazil Institution/Affiliation country: University of Campinas/BR